The Possibility of Application of Detected in Urine MicroRNA-15a for Diagnostics of Renal Cell Carcinoma

Mytsyk, Yulian; Dosenko, Victor E.; Borys, Yuriy; Ilchyshyn, О. V.; Chernova, NG; MYTSYK, O.; Maksymovych, I.R.; Illiuk, P.O.

doi:10.25040/ecpb2017.01.049

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nakada et al reported that 37 miRNAs were significantly under-expressed in conventional RCC, while the other 6 were overexpressed; miRNA 141 and miRNA-200 were especially down-regulated [58]. Mytsyk et al also compared the expression of miRNA-15a in the urine of healthy renal parenchyma/benign tumors and RCC patients, and they found that it was upregulated in the second case (p < 0.01) [59]. Liang et al explored the potential in diagnosis and prognosis of three miRNA signatures: miR-21, miR-584, and miR-155 [60].…”

Section: Prognosismentioning

confidence: 99%

The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common form of kidney cancer with 403,262 diagnoses and 170,000 deaths worldwide in 2018. Although partial or radical nephrectomy can be considered a successful treatment in early-stage or localized RCC, in advanced-stage disease, there is a high risk of metastasis or recurrence with a significantly poorer prognosis. Metastatic RCC is generally resistant to both chemotherapy and radiotherapy, and, despite several novel therapeutic agents, disease progression and mortality rates remain high. It is necessary to identify new diagnostic and therapeutic strategies for the management of this cancer. Knowledge of microRNA (miRNA) has consistently increased in the last year. miRNAs play an important role in several biological processes, such as cell proliferation, differentiation, and cell death. Due to this, miRNAs have been identified as an important key in different diseases, especially in cancer, and several studies show miRNAs as attractive tools and targets for novel therapeutic approaches. Recently several miRNAs (including miR-22, miR-203, miR-301 and miR-193a-3p) have been linked to dysregulated molecular pathways involved with the proliferation of cancerous cells and resistance to therapeutic agents. In the present study, recent data from studies assessing the application of miRNAs as biomarkers, therapeutic targets, or modulators of response to treatment modalities in RCC patients are analyzed.

show abstract

Section: Prognosismentioning

confidence: 99%

The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Direct interconnection between RCC size and miR-15a expression value was registered: the Pearson correlation coefficient was 0.873. In differentiation between RCC and benign renal lesions we achieved 98.1% specificity and 100% sensitivity (95% CI 0.9–1.0) at a cut-off value of 5,00E-06 relative fluorescence units (RFU), with AUC of the ROC curve 0.955 [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Potential clinical applications of microRNAs as biomarkers of renal cell carcinoma

Mytsyk

Dosenko

Skrzypczyk

et al. 2018

Cent european J Uro

View full text Add to dashboard Cite

IntroductionRenal cell carcinoma (RCC) accounts for 3% of adult malignancies and more than 90% of kidney neoplasms. High rates of undiagnostic percutaneous kidney biopsies and difficulties in reliable pre-operative differentiation between malignant and benign renal tumors using contemporary imaging techniques result in large numbers of redundant surgeries. Absence of specific biomarkers for early detection and monitoring complicates on-time diagnosis of the disease and relapse. For the patients followed up after having a nephrectomy, a noninvasive and sensitive biomarker enabling early detection of disease relapse would be extremely useful.Material and methodsThe study is a review of recent knowledge regarding potential clinical applications of microRNAs (miRNAs) as biomarkers of RCC.ResultsMicroRNAs are essential regulators of various processes such as cell proliferation, differentiation, development and death; they have been implicated in diverse biological and pathological processes in RCC. There is a class of miRNAs that promote RCC development (oncomirs) and a class of miRNAs that negatively regulate oncogenes, suppress tumor growth and invasion, and thus could be considered treatment agents (anti-oncomirs). Separate miRNAs and specific miRNAs expression profiles have been identified, enabling early detection of the disease, prediction of response to systemic therapy, or prognostication of biological behavior of the disease.ConclusionsThe miRNA network analysis and gene profiling may help to identify the most sensible molecular signatures of RCC that can be used for diagnostic purposes, as well as poor prognosis signatures and poor therapeutic response signatures in patients who undergo systemic therapy.

show abstract

“…In our previous work we have already described usefulness of expression of mi-R-15a measured in urine during RCC diagnostics [1]. Moreover, high miR-15a expression values have been significantly associated with poor survival rates in patients with RCC [2].…”

mentioning

confidence: 99%

“…In all patients' multiphase CT or MRI imaging with contrast enhancement has been performed prior to surgical treatment using standard abdominal protocols [6]. In all cases urine collecting and miR-15a expression measuring has been performed according to earlier described method, using quantitative polymerase chain reaction [1]. Associations between miR-15a expression and such RCC imaging features as necrosis, renal vein invasion, presence of intratumoral calcifications, definition of tumor margin and architecture, presence of collecting system invasion, intratumoral hypervascularity, homogeneous or nodular tumor enhancement pattern on nephrographic phase images have been assessed.…”

mentioning

confidence: 99%

Radiogenomics of Renal Cell Carcinoma: Our Clinical Experience

Mytsyk¹,

Borys²,

Dosenko³

et al. 2017

Eksp. klìn. fìzìol. bìohìm.

View full text Add to dashboard Cite

show abstract

The Possibility of Application of Detected in Urine MicroRNA-15a for Diagnostics of Renal Cell Carcinoma

Cited by 4 publications

References 13 publications

The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature

The Role of miRNA in the Management of Localized and Advanced Renal Masses, a Narrative Review of the Literature

Potential clinical applications of microRNAs as biomarkers of renal cell carcinoma

Radiogenomics of Renal Cell Carcinoma: Our Clinical Experience

Contact Info

Product

Resources

About